CDK1-driven phosphorylation networks promote glioblastoma progression via MAP1B-mediated microtubule destabilization

CDK1驱动的磷酸化网络通过MAP1B介导的微管去稳定化促进胶质母细胞瘤进展

阅读:2

Abstract

BACKGROUND: Glioblastoma (GBM) is the most aggressive and prevalent malignant brain tumor in adults, with poor prognosis despite current therapies. Cyclin-dependent kinase 1 (CDK1), a master regulator of cell cycle progression, has been implicated in oncogenesis, but its downstream phosphorylation network in GBM remains incompletely defined. METHODS: CDK1 expression was examined in clinical GBM tissues and cell lines. Functional studies were performed in U251 cells using CDK1-specific shRNAs. Label-free phosphoproteomic profiling and bioinformatics analyses were conducted to map CDK1-regulated signaling pathways and substrates. Prognostic associations were evaluated using Clinical Proteomic Tumor Analysis Consortium (CPTAC) datasets, and functional assays were used to validate candidate substrates. RESULTS: CDK1 was significantly upregulated in GBM tissues, and its knockdown suppressed proliferation, migration, and invasion of U251 cells. Phosphoproteomic analysis identified 15,156 phosphorylation sites, of which 2,836 were significantly altered by CDK1 inhibition, implicating pathways related to cell cycle regulation, DNA replication, and DNA damage repair. Subcellular localization revealed nuclear enrichment, including phosphorylation changes in RB1 and TP53. Importantly, CDK1-mediated hyperphosphorylation of microtubule-associated protein 1B (MAP1B) at multiple residues (Ser832, Ser1260, Ser1899, Ser1939, Ser2209, Ser2271) correlated with poor prognosis and promoted microtubule destabilization. Functional assays confirmed that MAP1B knockdown impaired GBM cell growth, migration, and invasion. CONCLUSION: This study demonstrates that CDK1 is a critical oncogenic driver in GBM, regulating broad phosphosignaling networks and promoting tumor progression via MAP1B-dependent microtubule destabilization. MAP1B phosphorylation emerges as a potential prognostic biomarker. These findings support the development of CDK1-targeted therapies, alone or combined with microtubule-stabilizing agents, for improved GBM management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。